Products
Greziprubart Biosimilar Monoclonal Antibody (Complement C5) for Research
Cat No.: GMP-Bios-INN-1223
Anti-C5 therapeutic antibody (Pre-made Greziprubart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Greziprubart (development code STSA-1002) is a monoclonal antibody targeting complement C5. It is developed by Staidson Beijing BioPharmaceuticals for acute respiratory distress syndrome and SARS-CoV-2 related conditions. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1223-1mg | 1mg | 3090 |
| GMP-Bios-INN-1223-10mg | 10mg | |
| GMP-Bios-INN-1223-100mg | 100mg | |
| GMP-Bios-INN-1223-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Greziprubart biosimilar, Whole mAb, Anti-C5 Antibody: Anti-C5/CO5/Complement C5/C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 therapeutic antibody |
| INN Name | Greziprubart |
| Target | C5 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | Staidson Beijing BioPharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Adult respiratory distress syndrome;SARS-CoV-2 acute respiratory disease;Vasculitis |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
